Search Results - "Dray, Sheldon"

Refine Results
  1. 1

    Conversion of Non-Immune Rabbit Spleen Cells by Ribonucleic Acid of Lymphoid Cells from an Immunized Rabbit to Produce IgG Antibody of Foreign Light Chain Allotype by Bell, Clara, Dray, Sheldon

    Published in The Journal of immunology (1950) (01-08-1970)
    “…Spleen cells (SpC) from non-immunized rabbits were converted to antibody “indirect” plaque-forming cells (PFC) by incubating them with ribonucleic acid (RNA)…”
    Get full text
    Journal Article
  2. 2

    The Cell-Migration-Inhibition Correlate of Delayed Hypersensitivity by Thor, Daniel E., Dray, Sheldon

    Published in The Journal of immunology (1950) (01-09-1968)
    “…When nonsensitive cells were incubated with an RNA extract from lymph nodes of human donors sensitive to tuberculin purified-protein-derivative, histoplasmin…”
    Get full text
    Journal Article
  3. 3

    Antigen-Secreting Cells: Enumeration of Immunoglobulin-Allotype-Secreting Cells in Nonimmunized Rabbits by means of Hybrid-Antibody-Coated Erythrocytes in a Reverse Hemolytic Plaque Assay by Molinaro, Giuseppe A., Maron, Elchanan, Dray, Sheldon

    “…A reverse hemolytic plaque-forming cell (PFC) assay for the enumeration of immunoglobulin-(Ig)secreting cells in nonimmunized rabbits was developed by using…”
    Get full text
    Journal Article
  4. 4

    A Correlate of Human Delayed Hypersensitivity: Specific Inhibition of Capillary Tube Migration of Sensitized Human Lymph Node Cells by Tuberculin and Histoplasmin by Thor, Daniel E, Dray, Sheldon

    Published in The Journal of immunology (1950) (01-07-1968)
    “…The migration of human monocytic-phagocytic sensitive cells from lymph node tissue culture suspensions was consistently and specifically inhibited by 10 µg/ml…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8

    Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide by Mokyr, M B, Dray, S

    Published in Cancer research (Chicago, Ill.) (01-07-1983)
    “…Mice bearing a large s.c. MOPC-315 tumor can be cured by a dose of cyclophosphamide (CY) ranging from 15 to 200 mg/kg. However, the low (15 mg/kg) and the high…”
    Get full text
    Journal Article
  9. 9

    Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors by Hengst, J C, Mokyr, M B, Dray, S

    Published in Cancer research (Chicago, Ill.) (01-06-1981)
    “…A single i.p. injection of cyclophosphamide (CY), 15 mg/kg, was shown previously to be curative if administered to BALB/c mice 10 to 16 days post-MOPC-315…”
    Get full text
    Journal Article
  10. 10

    Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy by LAUDE, M, RUSSO, K. L, MOKYR, M. B, DRAY, S

    Published in Cancer Immunology Immunotherapy (01-07-1993)
    “…We show here that in contrast to BALB/c mice bearing a late-stage, large MOPC-315 plasmacytoma, BALB/c mice bearing a late-stage, large RPC-5 plasmacytoma were…”
    Get full text
    Journal Article
  11. 11

    Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors by LAUDE, M, RUSSO, K. L, MOKYR, M. B, DRAY, S

    Published in Cancer Immunology Immunotherapy (01-03-1993)
    “…Previously we have established curative protocols for adoptive chemoimmunotherapy (ACIT) of mice bearing different plasmacytomas that are known to bear…”
    Get full text
    Journal Article
  12. 12

    Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas by LAUDE, M, SIESSMANN, K. L, MOKYR, M. B, DRAY, S

    Published in Cancer research (Chicago, Ill.) (01-09-1991)
    “…The incorporation of polyethylene glycol-6000 (PEG) into the culture media of tumor-infiltrated spleen cells (TISpC) and MOPC-315 stimulator tumor cells at a…”
    Get full text
    Journal Article
  13. 13

    Conversion of Non-Immune Spleen Cells by Ribonucleic Acid of Lymphoid Cells from an Immunized Rabbit to Produce γM Antibody of Foreign Light Chain Allotype by Bell, Clara, Dray, Sheldon

    Published in The Journal of immunology (1950) (01-12-1969)
    “…Spleen cells (SpC) from non-immunized rabbits were converted to antibody plaque-forming cells (PFC) by incubation with ribonucleic acid (RNA) extracts of…”
    Get full text
    Journal Article
  14. 14

    Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy by Mokyr, M B, Dray, S

    Published in Cancer investigation (1987)
    “…The results accumulated thus far illustrate that the therapeutic efficacy of many anticancer drugs depends not only on the direct tumoricidal/tumoristatic…”
    Get more information
    Journal Article
  15. 15

    Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors by Mokyr, M B, Hengst, J C, Dray, S

    Published in Cancer research (Chicago, Ill.) (01-03-1982)
    “…Previously, we had reported that a single i.p. injection of 15 mg cyclophosphamide (CY) per kg cured most mice bearing large MOPC-315 tumors (20 to 25 mm; Day…”
    Get full text
    Journal Article
  16. 16

    Three γ-Globulins in Normal Human Serum Revealed by Monkey Precipitins by Dray, Sheldon

    “…Precipitating antibodies specific for three normal human γ -globulins of relatively slow electrophoretic mobility were prepared in monkeys and demonstrated by…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19

    Serine proteinase inhibitors produced by human melanoma cell lines by Giacomoni, D, Najmabadi, F, Dray, S

    Published in Tumor biology (01-01-1990)
    “…The human melanoma cell lines M21 and MSM-M2 are shown to produce two similar competitive inhibitors of trypsin, a serine proteinase. These proteinase…”
    Get more information
    Journal Article
  20. 20